Ricostituzione ematopoietica a lungo termine dopo terapie antitumorali mieloablative e trapianto di progenitori ematopoietici circolanti

Translated title of the contribution: Long-term hematopoietic reconstitution following myeloablative antitumoral therapy and transplantation of circulating hematopoietic progenitors

Salvatore Siena, Marco Bregni, Massimo Di Nicola, Michele Magni, Fernando Ravagnani, Lorenza Gandola, Fabrizio Lombardi, Alessandro M. Gianni

Research output: Contribution to journalArticle

Abstract

Background: It remains unknown if hematopoiesis reconstituted by autografting with the sole peripheral blood hematopoietic progenitors (CPCs) after myeloablative high dose radiotherapy and/or chemotherapy is durable and capable of coping with increased demand due to boost radiotherapy, surgery, or infection. Patients and Methods: Durability of hematopoiesis was evaluated in 34 consecutive cancer patients treated with myeloablative total body irradiation (n = 17, median follow-up 3 years, range 3-49 months) and/or alkylating agent chemotherapy (n = 17, median follow-up 8 months, range 6-41 months) and autografted with CPCs because bone marrow autografting was contraindicated. CPCs (≤8 x 106 CD34+ cells/kg) had been collected during mobilization into the circulation in response to previous anticancer therapy and hematopoietic growth factor(s). Results: Following brief temporary pancytopenia, all patients achieved normal and durable hematopoiesis. The newly reconstituted hematopoietic system was capable of reacting favorably to stressful and noxious events such as surgery, radiotherapy, or varicella-zoster infection. No secondary irreversible failure of blood cell production occurred. Conclusions: The documentation of the durability of normal hematopoiesis following myeloablative cancer therapy and autografting with mobilized CPCs implies that the latter procedure, rather than solely an alternative to bone marrow autografting, represents an advantageous tool of choice permitting substantial amelioration of the therapeutic index of high-dose cancer therapy.

Translated title of the contributionLong-term hematopoietic reconstitution following myeloablative antitumoral therapy and transplantation of circulating hematopoietic progenitors
Original languageItalian
JournalTumori
Volume82
Issue number2 SUPPL.
Publication statusPublished - Mar 1996

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Long-term hematopoietic reconstitution following myeloablative antitumoral therapy and transplantation of circulating hematopoietic progenitors'. Together they form a unique fingerprint.

  • Cite this